Sale!

ALK EML4 NSCLC Test

2,550 د.إ

-10%

The ALK EML4 NSCLC Test is a specialized diagnostic procedure designed to detect the presence of the ALK (Anaplastic Lymphoma Kinase) gene rearrangement in patients with non-small cell lung cancer (NSCLC). This genetic alteration involves the fusion of the EML4 (echinoderm microtubule-associated protein-like 4) gene with the ALK gene, leading to the expression of an abnormal ALK protein that contributes to the development and progression of lung cancer. Identifying the presence of this gene fusion is crucial for determining the suitability of targeted therapies that specifically inhibit the activity of the ALK protein, offering a personalized treatment approach that can significantly improve patient outcomes.

The test is available at DNA Labs UAE, a leading facility that specializes in advanced genetic testing and analysis. The cost of the ALK EML4 NSCLC Test at DNA Labs UAE is 2,550 AED. This investment enables healthcare providers to make informed decisions regarding the most effective treatment strategies for their patients, potentially leading to better prognosis and quality of life for those affected by this type of lung cancer.

Home  Sample collection service available

  • 100% accuaret DNA Results
  • Ranked as Most trusted Genetic DNA Lab
Guaranteed Safe Checkout

ALKEML4 NSCLC Test

At DNA Labs UAE, we offer the ALKEML4 NSCLC Test for the diagnosis of non-small cell lung cancer (NSCLC). This test helps identify the presence of the ALK/EML4 fusion gene, which has significant therapeutic implications for patients.

Test Details

The ALK/EML4 fusion gene is commonly found in NSCLC patients, particularly in non-smokers or light smokers. It is more frequently seen in younger patients with adenocarcinoma histology. This fusion gene is a result of a chromosomal rearrangement between the ALK gene and the EML4 gene.

When the ALK and EML4 genes fuse together, a fusion protein with constitutive kinase activity is produced. This abnormal kinase activity can drive the growth and survival of cancer cells, leading to the development and progression of NSCLC.

Test Components

  • Paraffin embedded tissue blocks

Test Type

Genetics

Method

FISH (Fluorescence In Situ Hybridization)

Doctor

Oncology

Test Department

This test is conducted in our Genetics department.

Pre Test Information

The ALKEML4 NSCLC Test can be done with a doctor’s prescription. However, it is not applicable for surgery and pregnancy cases or people planning to travel abroad.

Sample Condition

Tumor tissue

Price

2550.0 AED

Report Delivery

4-5 days

Therapeutic Implications

Testing for the ALK/EML4 fusion gene is crucial in NSCLC patients, as it determines eligibility for treatment with ALK inhibitors such as crizotinib, ceritinib, alectinib, and brigatinib. These targeted therapies have shown significant efficacy in ALK-positive NSCLC, leading to improved outcomes for patients.

At DNA Labs UAE, we prioritize providing accurate and timely results to our patients. Our ALKEML4 NSCLC Test is conducted using the FISH method, ensuring reliable and precise analysis.

If you suspect you may have NSCLC or have been diagnosed with NSCLC and want to explore targeted therapy options, consult with an oncologist and inquire about the ALKEML4 NSCLC Test. Early detection and personalized treatment can make a significant difference in your prognosis and quality of life.

Test Name ALKEML4 NSCLC Test
Components Paraffin embedded tissue blocks
Price 2550.0 AED
Sample Condition Tumor tissue
Report Delivery 4-5 days
Method FISH
Test type Genetics
Doctor Oncology
Test Department:
Pre Test Information ALK/EML4 (NSCLC) can be done with a Doctors prescription. Prescription is not applicable for surgery and pregnancy cases or people planing to travel abroad.
Test Details

ALK/EML4 is a fusion gene that is commonly found in non-small cell lung cancer (NSCLC). It is a result of a chromosomal rearrangement between the ALK (anaplastic lymphoma kinase) gene and the EML4 (echinoderm microtubule-associated protein-like 4) gene.

The fusion of these two genes leads to the production of a fusion protein, which has constitutive kinase activity. This abnormal kinase activity can drive the growth and survival of cancer cells, leading to the development and progression of NSCLC.

The ALK/EML4 fusion gene is primarily found in a subset of NSCLC patients who are non-smokers or light smokers. It is more commonly seen in younger patients and those with adenocarcinoma histology.

Detection of the ALK/EML4 fusion gene is important in NSCLC patients, as it has significant therapeutic implications. The presence of the fusion gene makes patients eligible for treatment with ALK inhibitors, such as crizotinib, ceritinib, alectinib, and brigatinib. These targeted therapies have shown significant efficacy in ALK-positive NSCLC, leading to improved outcomes for patients.

Therefore, testing for the ALK/EML4 fusion gene is recommended in NSCLC patients to identify those who may benefit from targeted therapy with ALK inhibitors.